What Investors Can Learn From Biogen's Drug Approval That No One Wants
Will Aduhelm's controversial approval signal a new normal for clinical trials?
Source: fool.com
📰 Pharmagellan Guide News
Pharmagellan Guide News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Pharmagellan Guide. Real-time updates on events, politics, business and more.
Investors: This Is the Gold Standard of Biotech Trials
Trial design may matter more than you think.
Source: fool.com
Should Biotech Investors Hold Out Hope After a Failed Clinical Trial?
What happens after a trial's results are negative -- or positive?
Frank David Biotech Show Pharmagellan Guide Analyzing Biotech Clinical Trials New England Journal Trial Was Positive
Source: fool.com
Will the COVID-19 Vaccine Speed Up Biotech Production?
The pandemic accelerated the pace of vaccine development and approval. Are faster approvals here to stay?
Frank David Taylor Carmichael Biotech Show Motley Fool Pharmagellan Guide Analyzing Biotech Clinical Trials
Source: fool.com
Why Biotech Stocks Fall After Positive Clinical Trials
Positive clinical results should be a good thing, right?
Brian Orelli Frank David Biotech Show Motley Fool Pharmagellan Guide Analyzing Biotech Clinical Trials
Source: fool.com
Should Biotech Investors Care About Early Stage Clinical Trials?
Phase 1, phase 2, phase 3 -- what's the point of having so many clinical trials?
Frank David Taylor Carmichael Biotech Show Motley Fool Pharmagellan Guide Analyzing Biotech Clinical Trials
Source: fool.com
One Risk-Reward Profile Investors Should Watch in Biotech Trials
Author Dr. Frank David breaks down what investors should look for when it comes to trial design.
Brian Orelli Frank David Biotech Show Motley Fool Pharmagellan Guide Analyzing Biotech Clinical Trials
Source: fool.com